TY - JOUR
AU - Taburet, Anne-Marie
AB - The efficacy of HIV-1 protease inhibitors (PIs) as part of highly active antiretroviral therapy is now well established and has provided benefits to many patients with HIV infection. Atazanavir is a new azapeptide PI compound that was recently approved in the US and Europe. Atazanavir is recommended in combination with other antiretroviral agents for the treatment of HIV-1 infection.
TI - Clinical Pharmacokinetics and Summary of Efficacy and Tolerability of Atazanavir
JF - Clinical Pharmacokinetics
DO - 10.2165/00003088-200544100-00003
DA - 2012-09-30
UR - https://www.deepdyve.com/lp/springer-journals/clinical-pharmacokinetics-and-summary-of-efficacy-and-tolerability-of-ADu2mSpplQ
SP - 1035
EP - 1050
VL - 44
IS - 10
DP - DeepDyve
ER -